



Intercell provides update on Phase III trial for Travelers' Diarrhea Vaccine Patch

Vienna (Austria) and Gaithersburg (USA), April 29, 2009 – Intercell AG (VSE: ICLL) today informed regulators, partners and other parties involved in its planned pivotal Phase III efficacy study for the investigational Travelers' Diarrhea Vaccine that the company will wait to initiate this clinical trial until the swine flu outbreak in Mexico has resolved.

"It is the company's highest priority to assure the safety of the individual subjects who would travel to Mexico or Guatemala to participate in the study. As those travelers today could be at a high risk of contracting swine flu, it is clear that as a consequence, Intercell will not initiate this Phase III trial at the present time.", explained Gerd Zettlmeissl, CEO of Intercell.

In the planned Phase III pivotal efficacy study, known as the "Trek Study", 1,800 subjects from Europe and the United States are to be enrolled, vaccinated, and followed during travel to Mexico or Guatemala for the development of diarrhea.

Intercell will closely monitor the situation and work with local, national and international health authorities to identify the appropriate timing for the start of this study. The Company will continue with the preparatory processes for the study, which will commence pending resolution of the swine flu situation and is confident that the current development plans and timelines for the product should remain unchanged.

About Travelers Diarrhea

Travelers' diarrhea is most commonly caused by enterotoxigenic *Escherichia coli* (ETEC). An estimated 10 million travelers succumb to diarrhea illness annually with the highest risk in developing countries of Latin America, Africa, Asia and the Middle East. The illness usually results in increased frequency, volume and weight of stool. Typically, a traveler experiences four to five loose or watery bowel movements each day, with symptoms of nausea, vomiting, abdominal cramping, bloating, and general feeling of discomfort lasting, on average, 3-5 days. During this time, subjects are considered incapacitated or bedridden, and/or are unable to participate in planned activities.

About Intercell AG

Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell's vaccine to prevent Japanese Encephalitis is the Company's first product licensed for use.

The Company's technology platforms include an antigen-discovery system, adjuvants and a novel patch-based delivery system. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, and Sanofi Pasteur.





The Company's pipeline includes a Travelers' Diarrhea Vaccine Patch (Phase II), a Pseudomonas vaccine candidate (Phase II), a Vaccine Enhancement Patch with infected Pandemic Influenza vaccines (one shot plus patch, Phase II), a Phase II vaccine program for S. aureus, which is being developed with Merck & Co. Inc. (Phase II/III), as well as a vaccine candidate for Pneumococcus (Phase I). In addition, three other products focused on infectious diseases are in pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information, please visit: www.intercell.com

Contact

Intercell AG

Lucia Malfent

Head of Corporate Communications

Campus Vienna Biocenter 3, A-1030 Vienna

P: +43-1-20620-1303

Mail to: LMalfent@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.